Brian Skorney
Stock Analyst at Baird
(3.29)
# 1,015
Out of 5,154 analysts
117
Total ratings
44.58%
Success rate
4.43%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $86.30 | +1.97% | 6 | Dec 9, 2025 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $20.76 | +5.97% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $16.71 | -10.23% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $38.23 | +62.18% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $9.92 | +424.19% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $128.13 | +45.17% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $39.68 | +204.94% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $14.86 | +115.34% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $184.87 | +37.93% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $759.86 | -22.75% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $143.93 | -30.52% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $11.34 | +164.55% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $13.54 | +47.71% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $26.90 | -7.06% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $369.53 | -41.82% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $6.85 | +308.76% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.65 | +350.87% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $41.94 | +50.21% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $456.69 | -28.84% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $26.66 | -62.49% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.61 | +44,329.82% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.90 | +53.85% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.99 | +30,203.03% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $86.30
Upside: +1.97%
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $20.76
Upside: +5.97%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $16.71
Upside: -10.23%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $38.23
Upside: +62.18%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $9.92
Upside: +424.19%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $128.13
Upside: +45.17%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $39.68
Upside: +204.94%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $14.86
Upside: +115.34%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $184.87
Upside: +37.93%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $759.86
Upside: -22.75%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $143.93
Upside: -30.52%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.34
Upside: +164.55%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $13.54
Upside: +47.71%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $26.90
Upside: -7.06%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $369.53
Upside: -41.82%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $6.85
Upside: +308.76%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.65
Upside: +350.87%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $41.94
Upside: +50.21%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $456.69
Upside: -28.84%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $26.66
Upside: -62.49%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.61
Upside: +44,329.82%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.90
Upside: +53.85%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.99
Upside: +30,203.03%